-
Company Profile
SIGA Technologies Inc – Company Profile
SIGA Technologies Inc (SIGA) is a company that provides health security services. The company develops and commercializes solutions for serious unmet medical needs and threats. It offers an antiviral drug to treat smallpox disease. SIGA offers TPOXX products like oral, iv, liquid and post-exposure. The company’s Tecovirimat is combined with smallpox vaccines to prevent disease and reduce vaccine-related complications. It also develops orally administered small molecule therapeutics for the treatment and prevention of diseases caused by viruses. The company provides...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tecovirimat
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tecovirimat Drug Details Tecovirimat (Tpoxx / ST-246) is an antiviral agent. It is formulated...
-
Product Insights
Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain, and vomiting. This is followed by the development of rashes on the face, hands, forearms, and trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification. The Smallpox drugs in development market research report provide...